MedTrace Logo

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

NCT01761526 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-10-20

No results posted yet for this study

Summary

To investigate the Pharmacokinetics (PK) of transdermally delivered Rotigotine in Japanese and Caucasian Female and Male Healthy Subjects.

Conditions

  • Healthy

Interventions

DRUG

Rotigotine transdermal patch

Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)

Sponsors & Collaborators

  • Schwarz BioSciences GmbH

    collaborator UNKNOWN

  • Alfred-Nobel-Str. 10

    collaborator UNKNOWN

  • 40789 Monheim am Rhein

    collaborator UNKNOWN

  • UCB BIOSCIENCES GmbH

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2002-10-31
Completion
2002-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761526 on ClinicalTrials.gov